Rather than inventing from scratch, InMedx licensed its advanced heart-rate variability algorithm from Omega Wave, a company serving pro sports teams. This allowed them to leverage a proven, precise technology and focus their resources on the higher-value activities of clinical validation and securing FDA clearance for medical use.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

The core innovation for the Cobra OS wasn't a complex discovery but the disciplined application of a known principle: miniaturizing endovascular devices always makes them safer. By focusing on shrinking the device, they inherently improved safety by reducing the size of the arterial access site.

Augurex's CEO identified a major opportunity by noting that biomarker use in rheumatology was 10-15 years behind oncology. This "technology lag" between medical specialties signals a significant unmet need and a prime area for innovation, allowing proven concepts from one field to revolutionize another.

Transgene pivoted from "off-the-shelf" to individualized cancer vaccines not by starting over, but by leveraging its deep, four-decade-long expertise in viral vectors and payload integration. This highlights how legacy know-how can be a critical asset in strategic company shifts.

Successful MedTech innovation starts by identifying a pressing, real-world clinical problem and then developing a solution. This 'problem-first' approach is more effective than creating a technology and searching for an application, a common pitfall for founders with academic backgrounds.

Paragon Therapeutics operates a venture creation factory. Instead of discovering new targets, it applies its core half-life extension technology to validated biologics to create improved "bio-better" versions. It then spins these assets out into disease-focused companies like Spire (IBD), de-risking development by focusing on engineering and execution rather than novel biology.

Negative clinical trial results should not be seen as complete failures. Dr. Adam Arthur explains that even when an intervention fails its primary goal, the data provides crucial learnings that redirect research toward more promising pathways for patient care.

R&D departments in large pharmaceutical companies often resist repurposing projects. Their leaders are rewarded for discovering new chemical entities, not for finding new applications for existing drugs, creating an internal funding barrier that business units must overcome.